Phase III anti-HIV microbicide trial in Africa and India stopped as preliminary results show gel may increase risk of infection.
D000349:Africa / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage* / Q000009:adverse effects; D002482:Cellulose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D005260:Female; D005782:Gels; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007194:India / Q000453:epidemiology; D012307:Risk Factors
D019380:Anti-HIV Agents; D000891:Anti-Infective Agents, Local; D005782:Gels; D002482:Cellulose; C020254:cellulose sulfate